By understanding the molecular mechanisms underlying the dysregulation of TOP2A in gliomas, researchers may identify potential strategies to modulate its activity or expression, leading to improved therapeutic outcomes for patients with this aggressive brain tumor. This evidence concerns the gene TOP2A and central nervous system cancer.